VistaGen Therapeutics (VTGN) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Biodegradable Clean Climate Ecosystem Environment Environmental Forest Intensity Life Cycle Materials Natural Resources Nature Offset Packaging Pandemic Raw Materials Toxic Waste Access African American Asian Attrition Benefits Black California Consumer Privacy Act Collective Bargaining Community Culture Customer Cybersecurity Data Privacy Data Security Death Demographic Demographics Disability Diversity Diversity and Inclusion Drug Pricing Employee Engagement Ethnicity Gender Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injuries Injury Latinx LGBTQ Minority Opioid Perquisites Privacy Product Quality Recall Recruitment Reimbursement Retention Retirement Safety Satisfaction Skills Social Society Supplier Supply Chain Talent Training Union Volunteer Women Workers Workforce Working Condition Assessment Assurance Attorney General Attorneys General Audit Bonus Chronic Classified Commitment Corporate Governance Corporate Purpose Department of Enterprise Risk Management ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Perquisite Procurement Purpose Quality Standard R&D Reputation Reputational Research and Development Responsibility Responsible Special Meeting Strategy Sustainable Targets Tax Tenure Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On October 28, 2022, Vistagen Therapeutics, Inc. (the “Company”) reconvened its 2022 Annual Meeting of Stockholders (the “Reconvened Annual Meeting”) to consider and vote on Proposal Nos. 5 and 6. The results of the voting at the Reconvened Annual Meeting are set forth below.

Proposal No. 5 – Approval of Discretionary Authorization to Implement a Reverse Stock Split

		For			Against			Abstain
Votes		104,229,120			25,372,666			4,016,453

The vote required to approve Proposal No. 5, discretionary authority for the Company’s Board of Directors (the “Board”) to have the option to implement a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (“Common Stock”), at a ratio of between 1-for-2 and 1-for-30 (the “Reverse Split”), with the exact ratio to be determined by the Board, and the filing of an amendment to the Company’s Restated and Amended Articles of Incorporation, as amended, with the Nevada Secretary of State to effect the Reverse Split at any time as the Board may deem necessary and advisable prior to October 14, 2023, the one-year anniversary of the initial date of the Company’s 2022 Annual Meeting of Stockholders (the “Annual Meeting”) (the “Reverse Split Authorization”), was the affirmative vote of a majority of the 206,836,945 outstanding shares of the Company’s Common Stock entitled to vote as of the record date for the Annual Meeting. Accordingly, stockholders approved the Reverse Split Authorization.

Proposal No. 6 – Approval of an Amendment to the Company’s Bylaws

		For			Against			Abstain
Votes		65,592,186			24,302,176			3,454,611

The vote required to approve Proposal No. 6 to amend the Company’s Second Amended and Restated Bylaws, as amended, to allow the Board in its sole discretion to determine, from time to time, the number of directors constituting the Board was the affirmative vote of a majority of the 206,836,945 outstanding shares of the Company’s Common Stock entitled to vote as of the record date for the Annual Meeting. Accordingly, stockholders did not approve Proposal No. 6.

Details of the results of voting on Proposal Nos. 1 through 4, which voting occurred on October 14, 2022 at the initial commencement of the Annual Meeting, are available in the Current Report on Form 8-K filed by the Company on October 19, 2022. For more information about the foregoing proposals, please review the Company’s Proxy Statement, filed with the Securities and Exchange Commission on August 31, 2022.